AbbVie

Open: 141.43 Close: 141.9 Change: 0.47

How to get information about AbbVie Stock without reading the whole internet.

How much time have you spent trying to decide whether investing in AbbVie? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, Abbvie, …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

AbbVie Inc. (ABBV) may see less pain from Humira sales decline as rival lags. The company is banking on its other immunology drugs Rinvoq and Skyrizi to offset the sales erosion. The average one-year price target for Abbvie is 168.38.

Today's News

AbbVie Inc. (ABBV) may see less pain from Humira sales decline as rival lags. The company is banking on its other immunology drugs Rinvoq and Skyrizi to offset the sales erosion. AbbVie and Calibr announce expanded strategic collaboration to advance several innovative preclinical and early-stage clinical assets. The pharma company alleges BeiGenes Brukinsa patent infringes on its patent for Imbruvica. AbbVies stock has lost 11.4% in the year so far against the industry’s 3.3% growth. To make up for the falling Humira sales, Abbvie is focused on launching its newer immunology drugs. AbbVie and Calibr expand strategic collaboration to advance several innovative preclinical and early-stage clinical assets. Calibr will present to Abbvie a certain number of new discovery targets and preclinical assets of mutual interest for option considerations. AbbVie spent over $4.6 billion more on shareholder returns than it did on research and development, according to the latest Accountable.US report. Fintel reports that on July 25, 2023,William Blair initiated coverage of Abbvie (ABBV) witha Market Perform recommendation. The average one-year price target for AbbVie is 168.38. The projected annual revenue for Abvieis 55,229MM, a decrease of 2.66%. AbbVie Inc. (ABBV) has a market cap or net worth of $250.35 billion. The average price target for Abbvie is $166.82, which is 17.56% higher than the current price. The beta is 0.54, so the price volatility has been lower than the market average. AbbVie receives positive chmp opinion for epcoritamab (tepkinly®) for the treatment of adults with relapsed/refractory diffuse large b-cell lymphoma (DLBCL) The final European Commission decision on this indication is anticipated this year. AbbVie announces first patient dosed in Phase 3 Step-Up HS study evaluating upadacitinib (RINVOQ) in adults and adolescents with moderate to severe hidradenitis suppurativa (HS) The first patient has been dosed. RINVOq is a selective JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. AbbVie is donating $35 million to help support underserved communities and healthcare systems working to address the impact of the COVID-19 global pandemic. These press releases remain on the website for historical purposes only.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

This document will help you to evaluate AbbVie without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, Abbvie, price, ABBV, sale, Calibr, several, and the most common words in the summary are: abbvie, stock, market, news, abbv, price, report, . One of the sentences in the summary was: The average one-year price target for Abbvie is 168.38.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #market #news #abbv #price #report.